Cargando…

Clofarabine desensitization: A case report: Leukemia research reports

We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney injury. Given previous prolonged remission achieved with clofarabine and cytarabine therapy years prior, rechallenge was undertaken upon discovery...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayes, Sarah M., Wasko, Justin A., Warlick, Erica Dahl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312643/
https://www.ncbi.nlm.nih.gov/pubmed/28229039
http://dx.doi.org/10.1016/j.lrr.2017.02.001
_version_ 1782508236548603904
author Hayes, Sarah M.
Wasko, Justin A.
Warlick, Erica Dahl
author_facet Hayes, Sarah M.
Wasko, Justin A.
Warlick, Erica Dahl
author_sort Hayes, Sarah M.
collection PubMed
description We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney injury. Given previous prolonged remission achieved with clofarabine and cytarabine therapy years prior, rechallenge was undertaken upon discovery of AML relapse. We designed a desensitization protocol performed with the first dose of clofarabine, leading to successful administration of the entire clofarabine/cytarabine treatment course. From this case we show promise for clofarabine rechallenge after prior hypersensitivity reactions in patients with few treatment options for relapsed AML.
format Online
Article
Text
id pubmed-5312643
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53126432017-02-22 Clofarabine desensitization: A case report: Leukemia research reports Hayes, Sarah M. Wasko, Justin A. Warlick, Erica Dahl Leuk Res Rep Article We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney injury. Given previous prolonged remission achieved with clofarabine and cytarabine therapy years prior, rechallenge was undertaken upon discovery of AML relapse. We designed a desensitization protocol performed with the first dose of clofarabine, leading to successful administration of the entire clofarabine/cytarabine treatment course. From this case we show promise for clofarabine rechallenge after prior hypersensitivity reactions in patients with few treatment options for relapsed AML. Elsevier 2017-02-13 /pmc/articles/PMC5312643/ /pubmed/28229039 http://dx.doi.org/10.1016/j.lrr.2017.02.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Hayes, Sarah M.
Wasko, Justin A.
Warlick, Erica Dahl
Clofarabine desensitization: A case report: Leukemia research reports
title Clofarabine desensitization: A case report: Leukemia research reports
title_full Clofarabine desensitization: A case report: Leukemia research reports
title_fullStr Clofarabine desensitization: A case report: Leukemia research reports
title_full_unstemmed Clofarabine desensitization: A case report: Leukemia research reports
title_short Clofarabine desensitization: A case report: Leukemia research reports
title_sort clofarabine desensitization: a case report: leukemia research reports
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312643/
https://www.ncbi.nlm.nih.gov/pubmed/28229039
http://dx.doi.org/10.1016/j.lrr.2017.02.001
work_keys_str_mv AT hayessarahm clofarabinedesensitizationacasereportleukemiaresearchreports
AT waskojustina clofarabinedesensitizationacasereportleukemiaresearchreports
AT warlickericadahl clofarabinedesensitizationacasereportleukemiaresearchreports